May. 7 at 11:59 AM
$VTRS
Guidance is soft
The pharmaceutical company posted adjusted earnings per share of
$0.59, beating the analyst consensus of
$0.51 by
$0.08. Revenue reached
$3.52 billion, surpassing the
$3.35 billion estimate and representing 8% reported growth compared to the first quarter of 2025. On an operational basis, revenue increased 3% YoY.
Despite the quarterly beat, investors focused on the company’s full-year outlook.
Viatris reaffirmed its fiscal 2026 EPS guidance range of
$2.33 to
$2.47, with a midpoint of
$2.40 that sits below the analyst consensus of
$2.44.
The company also maintained its revenue guidance of
$14.45 billion to
$14.95 billion, with the
$14.70 billion midpoint trailing the
$14.637 billion consensus estimate.
